Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) EPS (Weighted Average and Diluted) (2021 - 2025)

Kezar Life Sciences' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$1.53 for Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) rose 81.18% year-over-year to -$1.53; the TTM value through Sep 2025 reached -$8.44, up 54.4%, while the annual FY2024 figure was -$11.49, 18.16% up from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2025 was -$1.53 at Kezar Life Sciences, up from -$1.87 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.25 in Q2 2022 and bottomed at -$9.37 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$1.7 (2025), against an average of -$2.64.
  • The largest annual shift saw EPS (Weighted Average and Diluted) tumbled 3503.85% in 2022 before it soared 81.18% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.26 in 2021, then crashed by 3503.85% to -$9.37 in 2022, then surged by 52.61% to -$4.44 in 2023, then surged by 37.61% to -$2.77 in 2024, then skyrocketed by 44.77% to -$1.53 in 2025.
  • Per Business Quant, the three most recent readings for KZR's EPS (Weighted Average and Diluted) are -$1.53 (Q3 2025), -$1.87 (Q2 2025), and -$2.27 (Q1 2025).